RAY-0221

N/A

Report date: 2025/09/11 15:52:44

Base Information

Drug NameRAY-0221
Drug Alias NameRAY-0221RAY0221RAY001RAY-001
ClassificationSmall molecules
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsGlucose-Dependent Insulinotropic Polypeptide Receptor agonistsGlucagon receptor agonists
TargetsGlucagon-like peptide 1 receptorGlucose-Dependent Insulinotropic Polypeptide ReceptorGlucagon receptor
Therapy Area/IndicationsObesityDiabetes MellitusMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesGuangdong Raynovent Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Raynovent Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsObesityDiabetes MellitusMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A